InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Onconetix, Inc.

ONCO Clue Score34
United States Fiscal year ends December CIK 0001782107
$0.62 -5.24% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.62 +47.62% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 18 Feb 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2021Operating income−3.4Net income−3.4EPS, diluted−1.26Fiscal year 2022Operating income−13.5Net income−13.4EPS, diluted−1.10Fiscal year 2023Revenue0.1Operating income−36.0Net income−37.4EPS, diluted−87.45Fiscal year 2024Revenue2.5 +4,217.3%Operating income−56.5Net income−58.7EPS, diluted−1,823.39Fiscal year 2025Revenue0.8 −67.7%Operating income−17.9Net income−14.0EPS, diluted−16.56
FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a 0.1 2.5 0.8
Growth +4,217.3% −67.7%
Operating income −3.4 −13.5 −36.0 −56.5 −17.9
Net income −3.4 −13.4 −37.4 −58.7 −14.0
Growth
EPS, diluted −1.26 −1.10 −87.45 −1,823.39 −16.56

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2021Fiscal year 2022Fiscal year 2023Gross margin−1,927.9%Operating margin−61,634.5%Net margin−63,986.5%Free cash flow margin−23,235.0%Fiscal year 2024Gross margin41.8%Operating margin−2,238.0%Net margin−2,325.2%Free cash flow margin−416.9%Fiscal year 2025Gross margin77.6%Operating margin−2,190.0%Net margin−1,721.0%
FY2021FY2022FY2023FY2024FY2025
Gross margin n/a n/a −1,927.9% 41.8% 77.6%
Operating margin n/a n/a −61,634.5% −2,238.0% −2,190.0%
Net margin n/a n/a −63,986.5% −2,325.2% −1,721.0%
Free cash flow margin n/a n/a −23,235.0% −416.9% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2021Operating cash flow−2.0Capital expenditure−0.0Free cash flow−2.0Fiscal year 2022Operating cash flow−8.7Capital expenditure−0.0Free cash flow−8.7Buybacks−0.6Fiscal year 2023Operating cash flow−13.6Capital expenditure−0.0Free cash flow−13.6Fiscal year 2024Operating cash flow−10.5Capital expenditure−0.0Free cash flow−10.5Fiscal year 2025Operating cash flow−9.7
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −2.0 −8.7 −13.6 −10.5 −9.7
Capital expenditure −0.0 −0.0 −0.0 −0.0 n/a
Free cash flow −2.0 −8.7 −13.6 −10.5 n/a
Growth
Buybacks n/a −0.6 n/a n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash1.9Shareholders’ equity1.4Fiscal year 2022Cash25.8Shareholders’ equity22.4Fiscal year 2023Cash4.6Shareholders’ equity−5.6Fiscal year 2024Cash0.6Shareholders’ equity8.5Fiscal year 2025Cash5.2Shareholders’ equity15.8
FY2021FY2022FY2023FY2024FY2025
Cash 1.9 25.8 4.6 0.6 5.2
Shareholders’ equity 1.4 22.4 −5.6 8.5 15.8

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
n/a n/a 0.1 2.5 0.8
Growth +4,217.3% −67.7%
n/a n/a 1.2 1.5 0.2
n/a n/a −1.1 1.1 0.6
Growth −40.0%
1.3 4.1 1.9 0.2 n/a
2.1 9.4 14.8 11.2 7.0
−3.4 −13.5 −36.0 −56.5 −17.9
Growth
n/a −13.4 −37.4 −59.7 −14.0
675,730.0 3,158,873.0 −0.0 −1.0 0.0
−3.4 −13.4 −37.4 −58.7 −14.0
Growth
Per share
−1.26 −1.10 −87.45 −1,823.39 −16.56
−1.26 −1.10 −87.45 −1,823.39 −16.56
Growth
3.2 12.3 0.4 0.0 0.9
3.2 12.3 0.4 0.0 0.9
Growth +283.5% −96.5% −92.4% +2,803.0%

† The diluted share count jumps at 2022 and 2023 and 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 5 of 5 years on file.